

# Press Release

For further information:

Peter Friedli  
Neuhofstrasse 8  
8834 Schindellegi  
Tel: 044/283 29 00  
Email: peter.friedli@friedlicorp.ch

## New Venturetec with a loss for the period October 1, 2008 to March 31, 2009

### Results for the six months period ending March 31, 2009

Zug, May 8, 2009. New Venturetec closed the first six months for fiscal year 2008/09, ended March 31, 2009, with a loss of USD 51'453'598 compared with a loss of USD 17'352'316 in the same period 2007/08. The net asset value per share decreased from USD 25.07 to USD 14.78 which equals -41.05% during the reporting six month period. The share price in the same period decreased from CHF 13.50 to CHF 7.26, or -46.22%.

The net loss on investments of the reporting period is USD 50'541'880 compared to a loss of USD 14'978'147 in the same period 2008. The reasons for the loss are decreases in the values of the public and the private portfolio companies. The publicly held companies were influenced by the turbulences in the financial markets. The shares of Osiris Therapeutics traded -28.45% in the reporting period, which equals a loss of USD 22'551'178. The loss on Invenda Corporation, which shares traded -85.45% in the reporting period was USD 1,187,653. On the private portfolio the investment in Iperia had to be written off which led to a loss of USD 12'131'594. Further, adjustments on the valuations of private companies were made on Healagenics with USD 7'531'220, Wstore with USD 4'100'000 and Prolexys Pharmaceuticals with USD 2'374'219. The write downs in private companies is a result of the general market conditions and lower valuations of such investments. The details on the valuation of the privately held companies are described in the semi-annual report.

As of March 31, 2009, New Venturetec had seven investments with three investments valued higher than the investment costs and four below investment costs. The total value of investments is USD 97'412'115 which results in an unrealized loss of USD 13'146'911 against the costs of the investments. As of March 31, 2009 82.90% of the total investments are in biotechnology and 17.10% in technology. The largest position is Osiris Therapeutics (NASDAQ:OSIR) with 58.84% of total investments.

There was no management fee or board remuneration paid for the reporting period but rather accrued. Total operational costs for the first half of the fiscal year 2008/09 were USD 227'450; the accrued management fee was USD 753'610.

The semi-annual report, including financial statements for the reporting period can be downloaded from [www.newventuretec.com](http://www.newventuretec.com).

New Venturetec is a publicly traded Swiss investment company (SWX:NEV) which invests directly in venture capital companies predominantly in the USA in the areas biotechnology and technology.